Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

IMW 2019 | Myeloma: immunomodulatory therapy and CHIP

Tarek H Mouhieddine • 13 Sep 2019
IMW 2019
Multiple Myeloma Lenalidomide Pomalidomide Thalidomide

Tarek H Mouhieddine, MD, Dana-Farber Cancer Institute, Boston, MA, discusses the rationale behind the use of immunomodulatory therapy in the treatment of multiple myeloma and the importance of clonal hematopoiesis of undetermined potential (CHIP) at the International Myeloma Workshop (IMW) 2019, held in Boston, MA.

More from Tarek H Mouhieddine

Novel biomarkers for predicting disease progression in smoldering myeloma
1:41
Novel biomarkers for predicting disease progression in smoldering myeloma
Tarek H Mouhieddine • 8 Dec 2024
The current approach to risk stratification of smoldering myeloma
2:54
The current approach to risk stratification of smoldering myeloma
Tarek H Mouhieddine • 8 Dec 2024
PD-1 plus Tim-3 blockade to improve the anti-myeloma activity of T-cells of patients on talquetamab
4:43
PD-1 plus Tim-3 blockade to improve the anti-myeloma activity of T-cells of patients on talquetamab
Tarek H Mouhieddine • 8 Dec 2024
The evolution of clonal hematopoiesis and associated outcomes in multiple myeloma
5:20
The evolution of clonal hematopoiesis and associated outcomes in multiple myeloma
Tarek H Mouhieddine • 9 Dec 2023

Related Videos

A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
Tarek H Mouhieddine • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
Tarek H Mouhieddine • 15 Dec 2025
Motixafortide + G-CSF HSC mobilization in pts with myeloma following quadruplet induction therapy
1:40
Motixafortide + G-CSF HSC mobilization in pts with myeloma following quadruplet induction therapy
Tarek H Mouhieddine • 6 Dec 2025
WGS of cfDNA for assessment of MRD in high-risk smoldering multiple myeloma
2:13
WGS of cfDNA for assessment of MRD in high-risk smoldering multiple myeloma
Tarek H Mouhieddine • 8 Dec 2025
The content of VJHemOnc is intended for healthcare professionals